AR110414A1 - Anticuerpos que se unen específicamente a il-15 humana y usos de estos - Google Patents
Anticuerpos que se unen específicamente a il-15 humana y usos de estosInfo
- Publication number
- AR110414A1 AR110414A1 ARP170103614A ARP170103614A AR110414A1 AR 110414 A1 AR110414 A1 AR 110414A1 AR P170103614 A ARP170103614 A AR P170103614A AR P170103614 A ARP170103614 A AR P170103614A AR 110414 A1 AR110414 A1 AR 110414A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- specifically join
- human
- join human
- specifically
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5443—IL-15
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437143P | 2016-12-21 | 2016-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110414A1 true AR110414A1 (es) | 2019-03-27 |
Family
ID=62627610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103614A AR110414A1 (es) | 2016-12-21 | 2017-12-21 | Anticuerpos que se unen específicamente a il-15 humana y usos de estos |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11267883B2 (enExample) |
| EP (2) | EP3558369B1 (enExample) |
| JP (2) | JP7155126B2 (enExample) |
| KR (2) | KR20190097094A (enExample) |
| CN (1) | CN110234349B (enExample) |
| AR (1) | AR110414A1 (enExample) |
| AU (2) | AU2017382850B2 (enExample) |
| BR (1) | BR112019012570A8 (enExample) |
| CA (1) | CA3046387A1 (enExample) |
| CL (1) | CL2019001729A1 (enExample) |
| DK (1) | DK3558369T3 (enExample) |
| EA (1) | EA201991514A1 (enExample) |
| ES (1) | ES3026508T3 (enExample) |
| FI (1) | FI3558369T3 (enExample) |
| HR (1) | HRP20250482T1 (enExample) |
| HU (1) | HUE071878T2 (enExample) |
| IL (1) | IL267113B2 (enExample) |
| LT (1) | LT3558369T (enExample) |
| MA (1) | MA47130B1 (enExample) |
| MD (1) | MD3558369T2 (enExample) |
| MX (2) | MX2019007357A (enExample) |
| PE (1) | PE20191497A1 (enExample) |
| PH (1) | PH12019501453A1 (enExample) |
| PL (1) | PL3558369T3 (enExample) |
| PT (1) | PT3558369T (enExample) |
| RS (1) | RS66900B1 (enExample) |
| SI (1) | SI3558369T1 (enExample) |
| UA (1) | UA126284C2 (enExample) |
| WO (1) | WO2018119246A1 (enExample) |
| ZA (1) | ZA201903848B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI695067B (zh) | 2013-08-05 | 2020-06-01 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| CN108368482A (zh) | 2015-09-18 | 2018-08-03 | 特韦斯特生物科学公司 | 寡核酸变体文库及其合成 |
| US11512347B2 (en) | 2015-09-22 | 2022-11-29 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
| EP3516528B1 (en) | 2016-09-21 | 2025-10-15 | Atlas Data Storage, Inc. | Nucleic acid based data storage |
| MA47130B1 (fr) | 2016-12-21 | 2025-05-30 | Cephalon, Inc. | Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations |
| JP2020508661A (ja) | 2017-02-22 | 2020-03-26 | ツイスト バイオサイエンス コーポレーション | 核酸ベースのデータ保存 |
| WO2018231872A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| US11407837B2 (en) | 2017-09-11 | 2022-08-09 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
| CA3079613A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
| KR20250069684A (ko) | 2018-01-04 | 2025-05-19 | 트위스트 바이오사이언스 코포레이션 | Dna 기반 디지털 정보 저장 |
| CN118957038A (zh) | 2018-05-18 | 2024-11-15 | 特韦斯特生物科学公司 | 用于核酸杂交的多核苷酸、试剂和方法 |
| EP3827079A1 (en) | 2018-07-25 | 2021-06-02 | Askgene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| US11828385B2 (en) | 2018-12-25 | 2023-11-28 | Ntn Corporation | Flow control valve seal and flow control valve device |
| WO2020139871A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| JP2022521551A (ja) | 2019-02-26 | 2022-04-08 | ツイスト バイオサイエンス コーポレーション | Ｇｌｐ１受容体の変異体核酸ライブラリ |
| US11492728B2 (en) | 2019-02-26 | 2022-11-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| WO2020257612A1 (en) | 2019-06-21 | 2020-12-24 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| CN115003697A (zh) | 2019-09-23 | 2022-09-02 | 特韦斯特生物科学公司 | Crth2的变异核酸文库 |
| US12173282B2 (en) | 2019-09-23 | 2024-12-24 | Twist Bioscience, Inc. | Antibodies that bind CD3 epsilon |
| CN115066518A (zh) * | 2019-12-09 | 2022-09-16 | 特韦斯特生物科学公司 | 针对腺苷受体的变体核酸文库 |
| EP4229093A1 (en) * | 2020-10-16 | 2023-08-23 | Genentech, Inc. | Anti-cleaved icaspase substrate antibodies and methods of use |
| JP2024504384A (ja) | 2021-01-21 | 2024-01-31 | ツイスト バイオサイエンス コーポレーション | アデノシン受容体に関する方法および組成物 |
| CN113185600A (zh) * | 2021-05-28 | 2021-07-30 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| KR20250044344A (ko) | 2022-08-04 | 2025-03-31 | 노파르티스 파르마 아게 | 아토피 피부염의 치료에 유용한 il-15 저해제 |
| CN118894934A (zh) * | 2023-05-05 | 2024-11-05 | 北京智仁美博生物科技有限公司 | 抗人il-15的抗体及其用途 |
| CN117209605B (zh) * | 2023-11-09 | 2024-01-30 | 北京百普赛斯生物科技股份有限公司 | 特异性结合il-15的抗体及其应用 |
| WO2025227052A1 (en) | 2024-04-26 | 2025-10-30 | Cephalon Llc | Doses and formulations of anti-il-15 antibody for the treatment of immune diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7132510B2 (en) | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
| US7329405B2 (en) * | 2001-08-23 | 2008-02-12 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
| US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| PT1425389E (pt) * | 2001-08-23 | 2012-02-07 | Genmab As | Anticorpos humanos específicos para interleucina 15 (il-15) |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2508375C (en) * | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| EA015897B1 (ru) * | 2003-02-26 | 2011-12-30 | Генмаб А/С | Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие |
| WO2006017853A2 (en) * | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
| WO2006090750A1 (ja) | 2005-02-28 | 2006-08-31 | Institute For Antibodies Co., Ltd. | 抗IgSF4抗体及びその利用 |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| SI2602323T1 (en) | 2007-06-01 | 2018-05-31 | Open Monoclonal Technology, Inc. | Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| DK2792236T4 (da) | 2009-07-08 | 2023-05-15 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| MX2012004412A (es) * | 2009-10-15 | 2012-05-08 | Abbott Lab | Proteinas de union a il-1. |
| EP4012714A1 (en) * | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| NZ604415A (en) | 2010-07-20 | 2014-10-31 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| JP5820688B2 (ja) | 2011-03-23 | 2015-11-24 | 株式会社Kri | 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法 |
| RU2014109038A (ru) * | 2011-08-23 | 2015-09-27 | Рош Гликарт Аг | Антитела к хондроитинсульфат протеогликану меланомы |
| BR112014009925B1 (pt) * | 2011-10-28 | 2022-09-20 | Teva Pharmaceuticals Australia Pty Ltd | Construtores de polipeptídeos e seus usos |
| EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP2963057A1 (en) * | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| JP6862351B2 (ja) | 2015-03-31 | 2021-04-21 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
| MX2018015363A (es) * | 2016-06-15 | 2019-04-15 | Amgen Inc | Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria. |
| UA128669C2 (uk) | 2016-10-14 | 2024-09-25 | Ксенкор, Інк. | ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra |
| MA47130B1 (fr) | 2016-12-21 | 2025-05-30 | Cephalon, Inc. | Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations |
-
2017
- 2017-12-21 MA MA47130A patent/MA47130B1/fr unknown
- 2017-12-21 UA UAA201908753A patent/UA126284C2/uk unknown
- 2017-12-21 EP EP17883800.9A patent/EP3558369B1/en active Active
- 2017-12-21 EP EP25165676.5A patent/EP4585261A3/en active Pending
- 2017-12-21 ES ES17883800T patent/ES3026508T3/es active Active
- 2017-12-21 AR ARP170103614A patent/AR110414A1/es unknown
- 2017-12-21 KR KR1020197019269A patent/KR20190097094A/ko not_active Abandoned
- 2017-12-21 US US16/471,616 patent/US11267883B2/en active Active
- 2017-12-21 SI SI201731602T patent/SI3558369T1/sl unknown
- 2017-12-21 PL PL17883800.9T patent/PL3558369T3/pl unknown
- 2017-12-21 DK DK17883800.9T patent/DK3558369T3/da active
- 2017-12-21 EA EA201991514A patent/EA201991514A1/ru unknown
- 2017-12-21 JP JP2019533652A patent/JP7155126B2/ja active Active
- 2017-12-21 IL IL267113A patent/IL267113B2/en unknown
- 2017-12-21 PE PE2019001283A patent/PE20191497A1/es unknown
- 2017-12-21 CA CA3046387A patent/CA3046387A1/en active Pending
- 2017-12-21 RS RS20250577A patent/RS66900B1/sr unknown
- 2017-12-21 MD MDE20191253T patent/MD3558369T2/ro unknown
- 2017-12-21 WO PCT/US2017/067917 patent/WO2018119246A1/en not_active Ceased
- 2017-12-21 AU AU2017382850A patent/AU2017382850B2/en active Active
- 2017-12-21 FI FIEP17883800.9T patent/FI3558369T3/fi active
- 2017-12-21 MX MX2019007357A patent/MX2019007357A/es unknown
- 2017-12-21 BR BR112019012570A patent/BR112019012570A8/pt unknown
- 2017-12-21 LT LTEPPCT/US2017/067917T patent/LT3558369T/lt unknown
- 2017-12-21 KR KR1020237031493A patent/KR102706743B1/ko active Active
- 2017-12-21 HU HUE17883800A patent/HUE071878T2/hu unknown
- 2017-12-21 PT PT178838009T patent/PT3558369T/pt unknown
- 2017-12-21 HR HRP20250482TT patent/HRP20250482T1/hr unknown
- 2017-12-21 CN CN201780079926.6A patent/CN110234349B/zh active Active
-
2019
- 2019-06-13 ZA ZA2019/03848A patent/ZA201903848B/en unknown
- 2019-06-19 MX MX2023014081A patent/MX2023014081A/es unknown
- 2019-06-20 CL CL2019001729A patent/CL2019001729A1/es unknown
- 2019-06-21 PH PH12019501453A patent/PH12019501453A1/en unknown
-
2022
- 2022-01-05 US US17/647,082 patent/US12410247B2/en active Active
- 2022-10-05 JP JP2022161059A patent/JP2022176324A/ja active Pending
-
2025
- 2025-02-20 AU AU2025201185A patent/AU2025201185A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110414A1 (es) | Anticuerpos que se unen específicamente a il-15 humana y usos de estos | |
| CL2021001920A1 (es) | Anticuerpos contra subunidad alfa il-7r y usos de estos | |
| MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| SV2017005367A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
| UY33202A (es) | Proteínas de unión a cd127 | |
| ECSP19059553A (es) | Anticuerpos anti-tgf-beta y su uso | |
| CL2017000651A1 (es) | Anticuerpos anti-glucagón y sus usos | |
| CL2018000457A1 (es) | Anticuerpos anti-mesotelina completamente humanos y células con efecto inmune dirigido a la mesotelina | |
| MX2016013332A (es) | Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas. | |
| CO2019005909A2 (es) | Anticuerpos y polipéptidos dirigidos contra cd127 | |
| MX2020006715A (es) | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. | |
| HRP20220131T8 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| UY35417A (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| PE20170519A1 (es) | Anticuerpos antagonistas del interferon alfa y omega | |
| EA201500744A1 (ru) | Комбинированная терапия с использованием антител к her3 и к her2 | |
| CR20170079A (es) | Agentes de unión a cd123 y usos de estos | |
| MX380520B (es) | Anticuerpos receptores de antitransferina y métodos de uso. | |
| PE20250392A1 (es) | Anticuerpos a la alfa-sinucleina y usos de los mismos | |
| CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
| PE20170192A1 (es) | Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad | |
| AR117566A1 (es) | Anticuerpos anti-trem-1 y sus usos | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
| MX2019005651A (es) | Metodos para tratar la obesidad con anticuerpos anti-angptl8. | |
| CO2019012756A2 (es) | Anticuerpos agonistas contra btla y sus usos |